BACKGROUND: Endogenous carbon monoxide (CO) at physiological concentrations is cytoprotective, whereas excess levels reflect underlying oxidative stress, inflammation, and vascular pathology and portend adverse clinical sequelae. However, the relation of exhaled CO to metabolic/vascular risk in the community is unknown. METHODS AND RESULTS: We related exhaled CO, a surrogate measure of blood CO concentration, to the risk of developing new-onset metabolic syndrome and incident cardiovascular disease following 14 943 routine examinations (4139 unique participants; mean age, 46 years, 53% women) in the Framingham Heart Study. Baseline exhaled CO was associated with the presence of cardiometabolic risk factors (including smoking) and prevalent metabolic syndrome (odds ratio, 1.09 per log CO; 95% confidence interval, 1.02 to 1.17; P=0.01). During up to 4 years of follow-up, 1458 participants developed new-onset metabolic syndrome, and 416 experienced a first cardiovascular disease event. Compared with individuals in the lowest quartile of exhaled CO, those in the highest quartile were more likely to develop metabolic syndrome (odds ratio, 1.48; 95% confidence interval, 1.25 to 1.76; P<0.0001) and cardiovascular disease events (hazard ratio, 1.66; 95% confidence interval, 1.14 to 2.40; P=0.008) in multivariable analyses that included adjustment for smoking status. CONCLUSION: In our community-based sample, higher exhaled CO levels predicted the development of metabolic syndrome and future cardiovascular disease events, underscoring the importance of this endogenous second messenger in the pathogenesis of metabolic and vascular risk.
BACKGROUND: Endogenous carbon monoxide (CO) at physiological concentrations is cytoprotective, whereas excess levels reflect underlying oxidative stress, inflammation, and vascular pathology and portend adverse clinical sequelae. However, the relation of exhaled CO to metabolic/vascular risk in the community is unknown. METHODS AND RESULTS: We related exhaled CO, a surrogate measure of blood CO concentration, to the risk of developing new-onset metabolic syndrome and incident cardiovascular disease following 14 943 routine examinations (4139 unique participants; mean age, 46 years, 53% women) in the Framingham Heart Study. Baseline exhaled CO was associated with the presence of cardiometabolic risk factors (including smoking) and prevalent metabolic syndrome (odds ratio, 1.09 per log CO; 95% confidence interval, 1.02 to 1.17; P=0.01). During up to 4 years of follow-up, 1458 participants developed new-onset metabolic syndrome, and 416 experienced a first cardiovascular disease event. Compared with individuals in the lowest quartile of exhaled CO, those in the highest quartile were more likely to develop metabolic syndrome (odds ratio, 1.48; 95% confidence interval, 1.25 to 1.76; P<0.0001) and cardiovascular disease events (hazard ratio, 1.66; 95% confidence interval, 1.14 to 2.40; P=0.008) in multivariable analyses that included adjustment for smoking status. CONCLUSION: In our community-based sample, higher exhaled CO levels predicted the development of metabolic syndrome and future cardiovascular disease events, underscoring the importance of this endogenous second messenger in the pathogenesis of metabolic and vascular risk.
Authors: H E Sabaawy; F Zhang; X Nguyen; A ElHosseiny; A Nasjletti; M Schwartzman; P Dennery; A Kappas; N G Abraham Journal: Hypertension Date: 2001-08 Impact factor: 10.190
Authors: Brian D Lamon; Frank F Zhang; Nitin Puri; Sergey V Brodsky; Michael S Goligorsky; Alberto Nasjletti Journal: Circ Res Date: 2009-09-10 Impact factor: 17.367
Authors: Suzaynn F Schick; Benjamin C Blount; Peyton Jacob; Najat A Saliba; John T Bernert; Ahmad El Hellani; Peter Jatlow; R Steven Pappas; Lanqing Wang; Jonathan Foulds; Arunava Ghosh; Stephen S Hecht; John C Gomez; Jessica R Martin; Clementina Mesaros; Sanjay Srivastava; Gideon St Helen; Robert Tarran; Pawel K Lorkiewicz; Ian A Blair; Heather L Kimmel; Claire M Doerschuk; Neal L Benowitz; Aruni Bhatnagar Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-05-18 Impact factor: 5.464
Authors: Matthew Nayor; Danielle M Enserro; Alexa S Beiser; Susan Cheng; Charles DeCarli; Ramachandran S Vasan; Sudha Seshadri Journal: Stroke Date: 2015-12-22 Impact factor: 7.914
Authors: Susan Cheng; Danielle Enserro; Vanessa Xanthakis; Lisa M Sullivan; Joanne M Murabito; Emelia J Benjamin; Joseph F Polak; Christopher J O'Donnell; Philip A Wolf; George T O'Connor; John F Keaney; Ramachandran S Vasan Journal: Eur Heart J Date: 2014-02-25 Impact factor: 29.983